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Abstract: Bacterial keratitis is a corneal infection which may cause visual impairment or even loss
of the infected eye. It remains a major cause of blindness in the developing world. Staphylococcus
aureus and Pseudomonas aeruginosa are common causative agents and these bacterial species are
known to colonise the corneal surface as biofilm populations. Biofilms are complex bacterial
communities encased in an extracellular polymeric matrix and are notoriously difficult to eradicate
once established. Biofilm bacteria exhibit different phenotypic characteristics from their planktonic
counterparts, including an increased resistance to antibiotics and the host immune response.
Therefore, understanding the role of biofilms will be essential in the development of new ophthalmic
antimicrobials. A brief overview of biofilm-specific resistance mechanisms is provided, but this is a
highly multifactorial and rapidly expanding field that warrants further research. Progression in this
field is dependent on the development of suitable biofilm models that acknowledge the complexity
of the ocular environment. Abiotic models of biofilm formation (where biofilms are studied on
non-living surfaces) currently dominate the literature, but co-culture infection models are beginning
to emerge. In vitro, ex vivo and in vivo corneal infection models have now been reported which use
a variety of different experimental techniques and animal models. In this review, we will discuss
existing corneal infection models and their application in the study of biofilms and host-pathogen
interactions at the corneal surface.
Keywords: microbial keratitis; bacterial keratitis; cornea; infection; biofilm; models; in vitro; ex vivo;
in vivo
1. Introduction
Bacterial keratitis is a potentially sight-threatening eye infection, localised to the cornea.
The infection is characterised by the presence of replicating bacteria on the ocular surface, which disrupt
the integrity of the corneal epithelium and result in inflammation of the corneal stroma [1].
Early symptoms include pain, redness, excessive lacrimation, light sensitivity and blurred vision.
Examination of the eye reveals lid oedema, congestion of conjunctiva, corneal haze and a variable
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degree of inflammation of the anterior chamber. The condition results in corneal scarring or in extreme
cases, corneal perforation and loss of the eye [2]. According to the World Health Organization, corneal
blindness is currently the fourth largest contributor to global blindness [3] and instances of ocular
trauma/corneal ulceration have been estimated to cause 1.5-2 million new cases of monocular blindness
per year [4]. Following ocular surface trauma, the cornea becomes highly susceptible to infection and
so many of these cases involve an infection component. Corneal infections may be caused by bacteria,
fungi, viruses or protozoans (collectively termed ‘microbial keratitis’) [5] but this review will focus
solely on bacterial keratitis. Bacterial species most commonly responsible for bacterial keratitis include
Staphylococcus aureus and Pseudomonas aeruginosa, although geographic variations in predominance
have been reported [6–8].
Predisposing Risk Factors
The healthy cornea is highly resistant to infection and so microbial keratitis rarely occurs
in the absence of predisposing risk factors [9]. Reported risk factors include corneal trauma,
contact lens-wear, chronic ocular surface disease, ocular surgery and systemic diseases associated with
an immunocompromised state [10,11]. These factors compromise the resistance mechanisms employed
by the cornea, rendering it newly susceptible to infection [9]. Although microbial keratitis occurs in
both developed and developing countries, there are large differences in the disease epidemiology
and aetiology [12]. In developing countries, corneal trauma constitutes the major risk factor in the
development of microbial keratitis and this is thought to reflect the increased size of the agricultural
workforce in these countries, e.g., rice stalks and thorns are a common cause of ocular injury for farmers
in South India [13,14]. Support for this is provided by a recent epidemiological study, conducted in
South India (n = 252). Ocular trauma was reported for 72% of microbial keratitis infections and 63%
of patients were employed as agriculturists [15]. In contrast, contact lens-wear constitutes the major
risk factor in the development of microbial keratitis in more developed countries. Studies conducted
in France and Sweden identified contact-lens wear as the major risk factor in ~50% of cases [10,16]
and steep rises in the incidence of microbial keratitis in developed countries have been linked to
the increased popularity of contact lenses. In Minnesota, a 435% increase in microbial keratitis was
recorded over a 39-year period, following the introduction of contact-lenses [17].
2. Biofilms
A biofilm has been defined as “a microbially derived sessile community characterized by cells
that are irreversibly attached to a substratum or interface or to each other, are embedded in a matrix of
extracellular polymeric substances that they have produced, and exhibit an altered phenotype with
respect to growth rate and gene transcription” [18]. Biofilms form on both biotic and abiotic surfaces
and are ubiquitous in infection. It is estimated that over 80% of microbial infections affecting the
human body involve a biofilm component [19], and this includes various ocular infections [20,21].
Biofilm formation has been directly visualised at the corneal surface during experimental corneal
infection [22] and bacteria obtained from corneal infections display biofilm forming activity [23,24].
The biofilm life-cycle (Figure 1) can be divided into three main stages: Initial attachment, biofilm
maturation and dissemination [25]. The process of dissemination creates particular challenges in the
treatment of biofilm infections, as it allows biofilm bacteria to regain their planktonic characteristics
and colonise distal sites within the body. As a result, many biofilm infections become chronic and are
recurrent in nature [26] and eradication of biofilms is further complicated by an enhanced resistance
phenotype [27–29]. Biofilm literature is currently dominated by abiotic models which lack any living
cells [30]. Numerous studies have investigated biofilm formation on contact lenses/lens cases, as well
as the efficacy with which different lens materials and disinfecting solutions can be used to reduce
bioburden [31–35]. However, these models lack crucial interaction between bacteria and animal/human
tissues. To understand various aspects of biofilm and their true implications it will be important that
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co-culture models investigating biofilm formation at the biotic surface are developed. In this review,
we will focus on the presence of biofilm at the biotic corneal surface.
 
 
Figure 1. The biofilm life-cycle. The biofilm life-cycle consists of three main stages: (1) Attachment:
Planktonic, free-living bacteria adhere to a surface. This is mediated by a combination of physical
factors (e.g., surface hydrophobicity, electrostatic interactions) and bacterial appendages (e.g., pili,
flagella). (2) Biofilm maturation: Adherent bacteria proliferate to form microcolonies. Bacteria produce
Extracellular Polymeric Substances (EPS), EPS matrix stabilises the bacterial network. (3) Dissemination:
A subset of bacteria detach, regain some of the characteristics of planktonic bacteria and colonise
distal sites.
3. Antibiotic Resistance in Biofilms
A major concern for the treatment of bacterial keratitis is the emergence of antibiotic resistance.
Two of the most common causative agents, S. aureus and P. aeruginosa, are ESKAPE pathogens:
an acronym used by the Infectious Diseases Society of America to describe 6 major pathogens
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, and Enterobacter species) that commonly cause nosocomial infections and that use
various antibiotic resistance mechanisms [36,37]. Furthermore, S. aureus and P. aeruginosa have
been identified by the World Health Organization as ‘High’ and ‘Critical’ priority targets, in the
development of new antibiotics [38]. Evidence of increasing antibiotic resistance among ocular isolates
is provided by longitudinal studies [39,40] and of particular concern is the observation that resistance to
fluoroquinolones is increasing for both Methicillin Susceptible (MSSA) and Methicillin Resistant (MRSA)
S. aureus strains [40]. In the UK, fluoroquinolones are currently used as the first-line antibiotic in the
treatment of bacterial keratitis [41]. Antibiotic resistance data for P. aeruginosa ocular isolates is varied,
with studies reporting Multi-Drug Resistant (MDR) isolates in the range of 6.52-42.9% [42,43]. Overall,
the US Department of Health and Human Services has reported that MDR P. aeruginosa constitutes
13% of all P. aeruginosa infections (n = 6700) [44]. Infections involving antibiotic resistant bacteria are
difficult to treat and often require combination antibiotics in high doses (fortified therapy) instead of
the standard fluoroquinolone monotherapy. Furthermore, increased levels of antibiotic resistance have
been linked to poorer clinical outcomes, with one study reporting a significant association between the
Minimum Inhibitory Concentration (MIC) of the treatment antibiotic(s) and the length of healing time
for corneal ulcers [45].
3.1. Mechanisms of Biofilm-Specific Antibiotic Resistance
To tackle the growing threat of antibiotic resistance, it is important that we understand the antibiotic
resistance mechanisms used by bacteria. Resistance is largely attributable to genetic mutations and
the acquisition of specific antibiotic resistance genes by horizontal gene transfer. Common genetic
mechanisms include the presence/overexpression of efflux pumps that remove antibiotics, stimulation
of modifying enzymes that inactivate antibiotics and the modification of bacterial target sites [46].
The formation of biofilms has also been associated with an increased resistance to antimicrobials [27].
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However, biofilm-specific antimicrobial resistance does not appear to be governed by the same
genetic elements that confer resistance in planktonic bacteria and dissemination of bacterial biofilms
has been associated with a return in susceptibility to antimicrobials [47]. This suggests that the
multicellular nature of biofilms is central in explaining biofilm-specific antibiotic resistance, a topic
more extensively reviewed elsewhere [48,49] and three main hypotheses that acknowledge the
importance of multicellularity have been proposed.
3.1.1. Limited Antimicrobial Penetration
One explanation is that the presence of a biofilm network limits antimicrobial penetration,
thereby preventing effective concentrations of antibiotic from reaching all of the cells in the population.
Not only does the presence of a biofilm act as a physical barrier, but antimicrobials may be deactivated
or sequestered within the extracellular matrix environment [50]. For instance, alginate, eDNA and
periplasmic glucans are all components of the P. aeruginosa biofilm environment that have been shown to
impede the movement of antibiotics [51,52]. Further support is provided by a recent study investigating
the relationship between antibiotic penetration and bacterial clearance. Antibiotics that diffused more
readily across S. aureus biofilms were associated with decreased bacterial recovery, demonstrating
that the ability to penetrate the biofilm matrix is important in reducing bacterial load [53]. However,
there is one major problem with this explanation, which is that if transport limitations were a major
factor in antibiotic resistance, we would expect the effectiveness of antibiotics to return once the biofilm
matrix became saturated with the drug compound. On the contrary, biofilm bacteria have been shown
to exhibit continued resistance at antibiotic concentrations that greatly exceed the minimum inhibitory
concentration (MIC) and minimum bactericidal concentration (MBC) [54,55].
3.1.2. The Presence of Altered Chemical Microenvironments
Further support for the idea that transport limitation does not play a major role in antimicrobial
resistance is provided by a study investigating the relative effects of antibiotic penetration, metabolic
activity and oxygen availability on the antibiotic resistant phenotype of P. aeruginosa biofilms [56].
The use of a diffusion bioassay revealed that both ciprofloxacin and tobramycin are able to
penetrate P. aeruginosa biofilms and that zones displaying greatest antibiotic resistance corresponded
with areas of low metabolic activity and oxygen concentration, rather than decreased antibiotic
concentration. These findings provide support for an alternative explanation, in which increased
resistance to antimicrobials is attributable to the presence of altered microenvironments within
biofilms. These microenvironments include areas of waste product build up, altered pH and
anaerobic niches that cause antimicrobials to work less effectively than they would in the bulk
environment [57,58]. The presence of these altered chemical environments not only interferes
with the activity of antimicrobials but also causes metabolic heterogeneity to arise within biofilms.
This heterogeneity makes it difficult for one single antimicrobial to target and kill all of the members of
the bacterial population.
3.1.3. Persister Cells
Another source of heterogeneity and a third explanation for biofilm-specific resistance is the
existence of phenotypic variants named ‘persisters’. This subset of cells constitutes a very small
proportion of the total bacterial population (~1%), but the presence of persisters has been documented
since the mid-1900s [59]. A recent Nature review article defined these cells as “a subpopulation of
transiently antibiotic-tolerant bacterial cells that are often slow-growing or growth-arrested, and are
able to resume growth after a lethal stress” [60]. The transcription of genes involved in energy
production is downregulated in persister cells [61] and a reduced growth phenotype exists prior
to antibiotic treatment [62]. Since many antibiotics work by targeting metabolic pathways, it has
been hypothesised that persister cells evade the bactericidal effects of antibiotics as a result of their
inactivity [60].
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4. Immune Evasion in Biofilms
During bacterial infections, host cell Pattern Recognition Receptors (PRRs) detect invading
pathogens via the recognition of Pathogen Associated Molecular Patterns (PAMPs). This stimulates an
innate immune response involving the activation of complement and various chemotactic signalling
pathways, which allow immune cells to be recruited to the site of infection [63,64]. Innate immune
cells such as polymorphonuclear neutrophils (PMNs) and macrophages are then able to kill invading
bacteria via phagocytosis and the production of bactericidal compounds (e.g., elastase enzymes,
lactoferrin and reactive oxygen species) [65]. When challenged by planktonic bacteria, the innate
immune response is highly efficient in its clearance of bacteria but the presence of bacterial biofilms has
been associated with an increased resistance to host defences [66,67]. Mechanisms of biofilm-specific
immune evasion include mechanical protection, shielding from immune recognition, changes in gene
expression and inhibition of immune cell functions [68–70]. It is important to note that there are
differences in the immune evasion strategies used by different bacterial species (heavily influenced by
EPS composition), but this review is focused solely on S. aureus and P. aeruginosa.
4.1. Role of Extracellular Polymeric Substances (EPS)
4.1.1. Mechanical Protection
Common to all bacterial biofilms, is the presence of an EPS matrix that encases the bacterial
cells. This matrix is important in aggregating the individual cells together and in doing so creates
a formidable barrier against phagocytosis. This killing mechanism is dependent on the engulfment
of bacteria and so phagocytes are only able to phagocytose bacterial targets up to their own cell
size. Therefore, when bacteria are aggregated together as biofilm populations, a dysfunction in
immune-cell-killing, termed “frustrated phagocytosis”, is observed [71,72]. In PMNs (cell size ~10 µm),
frustrated phagocytosis is observed at a polystyrene bead diameter of 11.2 µm, with only 50%
engulfment of bead circumference [73]. To overcome this size barrier, biofilm structures must be
broken apart. PMNs are predicted to exert attractive stresses of up to 1kPa that could facilitate biofilm
disruption. However, EPS matrix composition has been shown to influence resistance to mechanical
attack and in P. aeruginosa, increased expression of the Psl polysaccharide is associated with increases in
biofilm stiffness and intercellular cohesion between bacterial cells [74]. This led the authors to suggest
that changes in biofilm mechanics could allow biofilms to resist PMN stress, or at least delay biofilm
disruption long enough for bacterial PMN killing mechanisms to take effect.
4.1.2. Immune Recognition
As well as providing mechanical protection against phagocytosis, components of the EPS
also help to prevent immune recognition, thereby reducing phagocytic clearance. For instance,
coagulase expression causes fibrin to accumulate in the EPS environment of S. aureus biofilms [75],
this fibrous protein is known to protect staphylococci from opsonophagocytic killing [76]. In other
staphylococcal strains, polymeric-N-acetyl-glucosamine (PNAG) has been described as an antibody
“sink” and is shown to protect against the binding of IgG and C3b to biofilm-bacteria [77,78].
Although this has not been demonstrated in S. aureus, it is possible that similar principles could apply,
with EPS components acting as decoys for opsonisation and/or preventing direct targeting of the
biofilm bacteria [70]. In P. aeruginosa, alginate and Psl polysaccharide are major components of the EPS.
The presence of alginate has been shown to reduce both opsonic and non-opsonic phagocytosis [29,79],
with protection against opsonic antibodies mediated by O-acetylation of alginate [80]. Similarly,
the presence of Psl has been shown to reduce opsonic phagocytosis but via disruption of complement
binding [81].
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4.2. Changes in Gene Expression
The upregulation of genes encoding toxins and immune evasion proteins plays a major role in
the increased immune resistance of S. aureus biofilms. Upregulated toxins include Hla, LukAB/GH,
LukED, HlgAB, HlgCB and PSMs and upregulated immune evasion proteins include Eap, CHIPS, SAK
and SSL10 [70]. Gene expression is controlled by the accessory gene regulator (Agr) quorum sensing
(QS) system [82]. Interestingly, Agr dysfunction is common within S. aureus biofilm populations,
whereas there is a strong selective pressure against QS mutations in planktonic bacteria [83]. Agr controls
the expression of several protease enzymes involved in biofilm dispersal and so Agr mutants form thick,
dense biofilms [84,85] with an increased resistance to antibiotics [86]. Therefore, it has been suggested
that Agr heterogeneity may represent another biofilm specific host defence mechanism; the Agr
functional bacteria produce toxins that actively target host immune cells while Agr dysfunctional
bacteria strengthen the mechanical barrier against phagocytes [83,87]. P. aeruginosa bacteria also
undergo significant changes in gene expression following the switch to a biofilm lifestyle. Following
initial adhesion, there is a large increase in intracellular cyclic diguanylate monophosphate (c-di-GMP)
concentration [88]. This second messenger molecule controls the expression of over 500 genes, including
genes implicated in immune evasion [88,89]. For instance, c-di-GMP signalling induces a switch from
flagellar to twitching motility and downregulates the expression of PAMPs including the flagellum
and PcrV [90]. This prevents activation of the host NAIP/NLRC4 inflammasome and limits phagocyte
recruitment [91,92]. However, the importance of the host inflammasome in resolving P. aeruginosa
infections has been challenged [90].
4.3. Manipulation of Host Immune Cells
Despite the presence of the EPS, innate immune cells have been shown to penetrate both S. aureus
and P. aeruginosa biofilms [93,94]. However, this does not guarantee bacterial clearance, and within
this environment, immune cells are exposed to various host-killing mechanisms. For instance,
P. aeruginosa biofilms produce N-3-oxododecanoyl homoserine lactone (3-oxo-C12-HSL), a QS molecule
that induces apoptosis of both PMNs and macrophages [95]. Similarly, rhamnolipid biosynthesis has
been linked to PMN lysis in P. aeruginosa biofilms [96] and the production of various pore-forming
leukocidins is responsible for leukocyte cell death in S. aureus infections [97]. PMN lysis not only
prevents phagocytosis, but also enhances the formation of P. aeruginosa biofilms as biofilm bacteria can
incorporate host DNA and actin protein into their own EPS environment [98]. This increases biofilm
matrix stability and resistance to antimicrobials [99]. The biofilm-enhancing effects of PMN lysis have
been demonstrated in bacterial keratitis, with eDNA/F-actin acting as cellular scaffolds to promote
bacterial colonization [100]. Another way in which biofilm bacteria exploit host immune cells is via their
interactions with Neutrophil Extracellular Traps (NETs). NETs are formed of host DNA and granule
proteins and are produced by PMNs in response to infection [101]. They bind to and aggregate invading
bacteria, targeting them for host cell destruction. NETs play a particularly important role in P. aeruginosa
keratitis, preventing the spread of bacteria to the brain [102]. S. aureus circumvents NET activity
via the production of nuclease and adenosine synthase enzymes, which degrade the NET DNA into
deoxyadenosine (dAdo) [103,104]. This molecule is pro-apoptotic and causes the caspase-3-mediated
cell death of PMNs and macrophages [105], thereby preventing the phagocytic clearance of S. aureus
biofilms. Furthermore, biofilm bacteria are able to modulate immune cell behaviour via the production
of second messenger molecules such as cyclic diadenylate monophosphate (c-di-AMP). C-di-AMP
stimulates a type I interferon response in host cell macrophages and this is associated with an
anti-inflammatory M2 phenotype that facilitates the intracellular survival of S. aureus [106]. This is
an example of immune polarization, a phenomenon that is becoming increasingly recognised in the
persistent nature of biofilm infections. Various immune cells are able to adopt distinct phenotypes
(e.g., M1 vs M2 macrophages) and it appears pathogenic bacteria (including S. aureus and P. aeruginosa)
are able to skew the immune response towards a balance that facilitates chronic infection [107].
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5. Modelling Biofilm Infections
Bacteria have been shown to colonise the cornea as biofilm populations during bacterial keratitis.
To study corneal biofilm infections in a meaningful way, it is important that biofilm models are
representative of the true infectious scenario. Since abiotic models do not allow host–pathogen
interactions to be studied, they are unsuitable for many elements of infection research. Fortunately,
several biotic biofilm models that use in vitro, ex vivo or in vivo corneal systems have been developed.
However, there are various advantages and disadvantages associated with each of these models that
must be carefully considered (Table 1).
5.1. In Vitro Models
In vitro models use well-defined cell culture techniques to generate 3D corneal constructs. These
models are a popular choice for ophthalmological research due to their relative cost-effectiveness and
limited use of animals. The human cornea is composed of six distinct layers: epithelium, Bowman’s
layer, stroma, Pre-Descemet’s layer, Descemet’s membrane and endothelium [108,109] (Figure 2). As the
outermost layer, the corneal epithelium constitutes the first line of defence against external pathogens
and also acts as the major barrier against ocular drug penetration [110]. Therefore, many in vitro models
have focused solely on the cultivation of human corneal epithelial cell (HCE) multilayers [111,112].
However, 3D organotypic models have also been developed which incorporate epithelial, stromal and
endothelial cells, providing whole-tissue models [113–115].
 
 
Figure 2. Human corneal layers: (A) Schematic representation, and (B) haematoxylin and eosin staining.
The cornea has six distinct layers and the outermost layer is the corneal epithelium, which is made up of
5-7 rows of tightly packed corneal epithelial cells. These cells lie on an acellular, collagenous layer named
the Bowman’s layer and together the epithelium and the Bowman’s layer are essential in the protection
of the underlying stromal tissue. The stroma constitutes 90% of the overall thickness of the cornea
and is composed of mainly type I collagen and differentiated keratocytes. Beneath the stroma is the
Pre-Descemet’s layer (also known as Dua’s layer) and the Descemet’s membrane. These collagen-rich,
acellular layers separate the stromal tissue from the endothelium. The endothelium is composed of a
single layer of cells, which are mainly hexagonal in shape. This layer is adjacent to the anterior chamber
and constitutes the final layer of the cornea. Created with Biorender.com.
Another source of model diversity is the use of primary cells versus immortalized cell lines.
Primary cells are extracted directly from donor corneal tissue and therefore share the same phenotypic
and genotypic characteristics as the donor tissue. The drawback is that these cells have a finite lifespan
and reach senescence after only a few passages [116]. Furthermore, the availability of human corneal
tissue is highly limited as healthy tissue is generally reserved for keratoplasty. This means animal
corneas are often used as a source of primary corneal epithelial cells.
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The production of an immortalized cell line involves transfection/transformation of cells with a
virus or plasmid that induces the cells to enter a continuously growing state by activating telomere
maintenance mechanisms [117]. As a result, the cells may be continuously passaged, and cell lines are
commercially available. This makes immortalized cell lines attractive model systems, as they are easy
to assemble and economical. However, the underlying assumption that cell lines mimic all aspects of
the normal cornea has not been proven and with each passage, genetic drift occurs, causing cells to
become phenotypically distinct from the original cell population [118]. A study comparing the gene
expression profile of the HCE-T cell line to gene expression in the healthy human cornea, found changes
in gene expression for 36% of probed genes [119]. This is a reminder of the importance of characterising
cell lines to ensure they remain suitably representative of the ocular surface in vivo.
Existing In Vitro Infection Models
Drug permeation studies have been a key driver in the development of in vitro corneal models.
Curved filters have been used to produce monolayers that share the curvature of the cornea [120]
and optimisation of cell culture conditions has led to the development of corneal models with tight
cell junctions, epithelial barrier integrity and permeation profiles comparable to those of the excised
cornea [121,122]. The development of in vitro models for studying corneal absorption has been reviewed
previously [123,124] and optimised cell culture techniques are transferable to the development of
in vitro infection models. Such models have been used to investigate host–pathogen interactions at the
corneal epithelial surface. Immortalized HCE cell lines have been used to investigate receptor-mediated
adhesion mechanisms and identify key bacterial virulence factors (VFs) involved in invasion [125,126].
Modulation of the host response has also been studied, with a recent study demonstrating that the
type-III secretion system (T3SS) of P. aeruginosa is involved in subversion of antimicrobial peptide
(AMP) expression [127]. Furthermore, in vitro studies have demonstrated the importance of host cell
defences such as cell surface mucins and tear fluid. Knockdown of MUC16 in the HCLE cell line causes
significant decreases in epithelial barrier function [128] and exposure of primary rabbit corneal epithelial
cells to human tear fluid has been shown to confer significant cytoprotective effects, as well as reducing
the translocation of P. aeruginosa [129,130]. These in vitro infection models have helped to progress our
understanding of bacterial keratitis, but they are limited by the absence of a biofilm component. To the
best of our knowledge, an in vitro model that combines live HCE cells and the formation of bacterial
biofilm is yet to be reported. In contrast, multiple keratitis studies have investigated biofilm formation
on abiotic surfaces in the absence of cells [131,132]. As in vitro modelling techniques continue to
improve, co-culture models may be reported but there are various limitations associated with the use
of in vitro systems for studying biofilm infections [133]. For instance, characteristics of the biofilm
microenvironment (e.g., nutritional cues, presence of immune cells) [134–136] have been shown to
influence biofilm morphology and so differences in specific biofilm-forming conditions may limit
model applicability.
5.2. Ex Vivo Models
Ex vivo studies make use of whole, excised corneas that are maintained in an artificial environment
before experimentation. Animal corneas are often used due to the limited availability of human
corneas and so interspecies variation is one of the main problems with ex vivo studies. A lack of
standardised methods and paucity of information on animal models means comparing ex vivo studies
is difficult, and there is dispute regarding the suitability of different animal models. ex vivo models
used to investigate bacterial keratitis include mice [137–141], rabbits [140–146], goats [147], cows [148]
and pigs [149–151]. It is currently unknown if interspecies differences in the thickness of the corneal
epithelium [108,152] and stroma [153–155] play a major role in development and progression of infection
in the ex vivo cornea. Morphological aspects that may affect the development of infection between
species have been discussed previously [156] but many questions remain unanswered. Of particular
importance is the presence or absence of the Bowman’s layer. The Bowman’s layer is typically found in
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primate species but has not been found in all animals [157,158] and there is evidence that it functions
as an additional barrier to bacterial traversal [159]. The importance of this layer is influenced by the
method of infection. Popular infection methods include corneal scarification or intrastromal injection,
which bypass the Bowman’s layer and provide direct access to the corneal stroma. In these instances,
the protective role of the Bowman’s layer is less important, but other studies have used contact lenses
or blotting paper to introduce bacteria without prior wounding of the cornea. Such methods are
important for studying intrinsic corneal resistance and/or initial bacterial adhesion, and in these
studies, interspecies differences in the Bowman’s layer may compromise model suitability. There are
conflicting reports for rabbit and porcine corneas with some studies claiming the Bowman’s layer is
absent [160–163], while others report it as present [164,165]. Given the popularity of these two animal
models, it is important that resolution be reached on this topic.
Existing Ex Vivo Infection Models
Various techniques have been used to induce bacterial infection in ex vivo corneas,
including prolonged exposure to bacteria [166,167], use of infected contact lenses [149], superficial injury
(e.g., tissue paper blotting) [168], corneal scarification [146,147,151] and intrastromal injection [143].
Differences in infection method, inoculum size, culturing techniques, incubation times and bacterial
strains mean that comparing ex vivo studies is challenging. For example, Pinnock et al. [143] found
that more bacteria are recovered after injecting the inoculum into the stroma than after corneal
wounding. In contrast, similar infection outcomes were reported for both rabbit and human corneas.
Colony Forming Units (CFU) were measured following 24 or 48 h infection and variations in CFU
were small despite differences in bacteria and handling techniques for each model [143]. In agreement
with Pinnock et al., we recently demonstrated that there was no significant difference in viable cell
count between ex vivo porcine and rabbit cornea models after 24 h infection, nor when two different
strains of P. aeruginosa were used [151]. Furthermore, while some studies have reported that infection
in ex vivo corneas is easy to establish and that progress is visible within less than 24 h [143,151,167],
Madhu et al. found that incubation time could be extended by a few days if a smaller inoculum was
used [147]. Despite issues with standardisation, ex vivo models have been used to study various aspects
of bacterial keratitis. This includes: epithelial barrier function [137,169], effect of bacteria on epithelial
cell migration [150], bacterial transmission from contact lenses [145,149,170], bacterial adherence to
corneal epithelium [168], movement of bacteria in stroma [146], role of virulence factors [139,147] and
drug testing of new ophthalmic antimicrobials [132,148]. Despite the popularity of ex vivo corneal
infection models, biofilm formation under these conditions remains to be characterised. However,
our group is currently using an ex vivo porcine infection model to study bacterial distribution and
biofilm formation at the corneal surface [151] (Figure 3). Scanning Electron Microscopy (SEM) depicts
bacterial colonization under different infection conditions, indicating that ex vivo porcine models could
be useful in the study of established bacterial keratitis infections.
5.3. In Vivo Models
In vivo modelling involves the use of live animals. Rat [171] and rabbit [172–174] models have
been reported, but mouse models currently dominate the literature [131,137,138,175–178]. Despite its
smaller size, the murine cornea contains more corneal epithelial cell layers than the human cornea and
the ratio of epithelial to stromal cells is larger [179]. As with other animal models, there is a dispute
regarding the presence of a Bowman’s layer [164,165] and there are large interspecies differences in
immune response that must be considered [180]. However, murine models remain a popular choice
for in vivo work because of their small size, ease of breeding and the existence of large genetic mutant
libraries. Various techniques have been developed for studying bacterial keratitis in vivo. Animals are
first anesthetized so that corneal wounding/bacterial inoculation can be performed, and infection
progresses in the living model. Following scarification, the eyes are enucleated and analysed ex vivo or
alternatively, intravital imaging techniques have now been reported which allow microscopic analysis
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to be conducted in vivo [181]. in vivo corneal models are ideal for studies of host immune defences,
inflammation and corneal healing processes. However, these models are not suitable for studying the
early stages of infection, as the healthy, intact cornea is difficult to infect unless contaminated contact
lenses are used [138,182,183]. Additionally, initiating and developing infection takes days and is not
always guaranteed [182].
 
 
 
Figure 3. Scanning electron micrographs of ex vivo porcine corneas after 4 h Methicillin-Resistant
Staphylococcus aureus (MRSA) infection (A), 6 h MRSA infection (B), 24 h Pseudomonas aeruginosa infection
(C) and the uninfected porcine cornea (D). Arrows show MRSA adhering to corneal epithelial cells.
Existing In Vivo Infection Models
Increasing interest in ocular biofilms over the past decade has resulted in the development of an
established in vivo cornea model [177], followed by improved methods of imaging bacteria and biofilm
formation [22,131,137,139,176,181]. This has allowed researchers to begin to characterise the process of
biofilm formation at the ocular surface (Table 2). in vivo infection models have also played an integral role
in other areas of bacterial keratitis research, including: biofilm formation on contact lenses in rabbit [172]
and mice [175], host–pathogen interactions on ocular samples using proteomics [184,185], activation of
immune signalling pathways [186], the role of virulence factors in keratitis [142,173,178,187] and drug
testing of new ophthalmic antimicrobials [174,176,188]. Drug testing has included synthetic analogues
of host antimicrobial peptides, with one study reporting reduced corneal bioburden and improved
ocular scores following treatment with their lead peptide [188]. This suggests that synthetic AMP
analogues could provide valuable alternatives/adjuncts to antibiotics and highlights the importance
of ocular surface proteins in defence against bacterial keratitis [137,169,189]. For instance, surfactant
protein D (SP-D) present in tear fluid has been shown to take part in clearing P. aeruginosa from the
murine ocular surface [182], while exogenous vasoactive intestinal peptide regulates expression of
other proteins involved in infection [190]. However, it was recently found that there are differences
in protein expression between human and mouse stroma in vascularized and healthy corneas [191].
These differences are likely to affect pathophysiology between species and may limit the clinical
relevance of murine in vivo models.
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Table 1. Evaluation of in vitro, ex vivo and in vivo corneal models for the study of bacterial keratitis infections.
Advantages Disadvantages
in vitro cell culture models
 Economical.
 Reduced use of animals.
 Cell lines can be used continuously.
 3D organotypic models can be developed using multiple
cell lines.
 Many host defence mechanisms remain investigable, e.g.
expression of mucins, AMPs, pro-inflammatory cytokines and
microRNAs, investigation of cell surface receptors and PRR
signalling pathways.
 Problems with cell lines and genetic drift.
 Primary cells reach senescence after a few passages.
 Reduced cell viability and increased susceptibility to infection.
 Absence of resident and infiltrative immune cells.
 Absence of conjunctiva.
 Absence of tear fluid and lacrimal glands.
 Infection normally occurs under static conditions.
 Differences in the biofilm microenvironment (e.g. nutritional
cues, absence of immune cells) may affect biofilm morphology.
ex vivo models
 Whole-tissue model.
 Complex 3D surface topology of the cornea is preserved.
 Increased cell viability facilitates longer infection periods.
 Presence of resident immune cells.
 Low availability of human corneas means animal models are
commonly used.
 Lack of standardised infection methods.
 Dispute regarding corneal anatomy of animal models.
 Interspecies differences in corneal anatomy, functional
characteristics and immune response may affect applicability to
human infections.
 Absence of infiltrative immune cells.
 Absence of conjunctiva.
 Absence of tear fluid and lacrimal glands.
 Infection normally occurs under static conditions.
 Differences in the biofilm microenvironment (e.g. nutritional
cues, absence of immune cells) may affect biofilm morphology.
in vivo models
 Complete immune response (resident/infiltrative immune
cells, tear film, conjunctiva and lymphatic vessels).
 Infection occurs under dynamic, shear stress conditions.
 Biofilm morphology should be highly similar to the true
infectious scenario.
 Animal models must be used, raising ethical issues.
 Interspecies differences in corneal anatomy, functional
characteristics and immune response may affect applicability to
human infections.
 Expensive.
 Time-consuming.
 Infections can be difficult to establish and prior wounding of the
cornea is often required.
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Table 2. Biofilm characteristics of in vivo corneal infection models.
Animal
model
Pathogen Biofilm Characteristics Ref.
C57BL/6
black mice
Pseudomonas aeruginosa
ATCC 9027
 Rapid shift from planktonic to biofilm lifestyle
observed for all corneas.
 Microcolonies present on day 2 post-infection and
fibrous extracellular substances visible.
 Mature biofilm structures present on day 3. Bacteria
form as “mushroom shaped bodies” and “tower like
structures” and are embedded in a web of extracellular
polysaccharides.
 A thick, dense biofilm layer is observed on days 5-6.
Bacteria become static within this structure.
 Neutrophils migrate into the corneal stroma and
production of NETs is observed at early time points.
Neutrophils are localised to the biofilm surface once
mature biofilm structures develop.
[22]
C57BL/6
and Swiss
Webster
(SW) mice
Pseudomonas aeruginosa
PAO1-GFP and 6294-GFP
(clinical isolate)
 Early (12 h) biofilms are composed of bacterial
clusters/microcolonies that are thought to emanate from
the infected epithelial cells.
 Late (24 h) biofilms are composed of bacterial sheets.
 Biofilm bacteria are surrounded by Psl
polysaccharide but there is a low abundance of alginate.
 Biofilms are resistant to neutrophil infiltration.
[176]
BALB/c
mice
Staphylococcus aureus and
Fusarium falciforme
(clinical isolates)
 A mixed biofilm is observed after 72 h.
 S. aureus: Bacteria colonise the corneal epithelium
and a part of the stroma. Bacterial clusters observed,
including a large cocci aggregate at the site of the corneal
lesion. Bacteria secrete exopolysaccharides that form
“halos” around the bacteria and then merge with the
extracellular matrix of other cocci. Development of a
new blood vessel in the stroma is observed and
attributed to the host immune response.
 F. falciforme: Hyphae and conidia observed and
hyphae migrates through stroma to reach the
endothelium. F. falciforme structures are embedded in a
fibrin matrix within the stroma. Presence/growth of
fungi causes corneal collagen fibres to become
disorganised.
[131]
6. Conclusions
Bacterial keratitis is a serious corneal infection, characterised by biofilm formation at the ocular
surface. Biofilms are notoriously difficult to eradicate because of their increased resistance phenotype.
This includes an increased resistance to antimicrobials and biofilm-specific immune evasion mechanisms.
To study bacterial keratitis in a meaningful way, it is important that suitable test models exist.
The development of in vitro, ex vivo and in vivo models have all made significant contributions to our
understanding of bacterial keratitis. Infection models have allowed us to study the role of specific
bacterial virulence factors and constituents of the host immune response, as well as the complex
interactions that occur between them. However, there are various limitations associated with existing
infection models and these limitations must be carefully considered during experimental design
and interpretation of results. One particular challenge in the field is the development of co-culture
models that display mature biofilm architecture without compromising host viability. As a result,
the characterisation of corneal biofilms has mainly been explored in vivo. It is important that we
continue to optimise corneal biofilm models, as they represent a valuable tool for ophthalmological
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drug testing. The development of representative models will allow novel therapeutics to be identified
more easily and could ultimately help to reduce corneal blindness.
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